
## Elisabeth Aberer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5045143/publications.pdf Version: 2024-02-01



FUSARETH AREDED

#	Article	IF	CITATIONS
1	Nomenclature of Cutaneous Vasculitis. Arthritis and Rheumatology, 2018, 70, 171-184.	5.6	200
2	European Dermatology Forum S1â€guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1401-1424.	2.4	148
3	S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 2017, 31, 389-404.	2.4	117
4	Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 730-737.	0.9	82
5	European dermatology forum S1â€guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1581-1594.	2.4	79
6	A Clinical, Histological, and Immunohistochemical Comparison of Acrodermatitis Chronica Atrophicans and Morphea. American Journal of Dermatopathology, 1991, 13, 334-341.	0.6	58
7	Dapsone as Second-Line Treatment for Cutaneous Lupus Erythematosus? A Retrospective Analysis of 34 Patients and a Review of the Literature. Dermatology, 2016, 232, 91-96.	2.1	45
8	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 81-87.	3.8	42
9	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia, 2020, 34, 1090-1101.	7.2	34
10	Epidemiologic, socioeconomic and psychosocial aspects in lupus erythematosus. Lupus, 2010, 19, 1118-1124.	1.6	29
11	Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial. Lancet Infectious Diseases, The, 2017, 17, 322-329.	9.1	28
12	Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study. European Respiratory Journal, 2017, 50, 1601708.	6.7	28
13	Impaired quality of life in patients with systemic sclerosis compared to the general population and chronic dermatoses. BMC Research Notes, 2014, 7, 594.	1.4	25
14	Within European margins. Lancet, The, 2011, 377, 178.	13.7	19
15	Disease spectrum in patients with elevated serum tryptase levels. Australasian Journal of Dermatology, 2015, 56, 7-13.	0.7	19
16	Comparison of a Two- or Three-Week Regimen and a Review of Treatment of Erythema Migrans with Phenoxymethylpenicillin. Dermatology, 2006, 212, 160-167.	2.1	18
17	Course of Borrelia burgdorferi DNA Shedding in Urine after Treatment. Acta Dermato-Venereologica, 2007, 87, 39-42.	1.3	16
18	Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). American Journal of Blood Research, 2013, 3, 174-80.	0.6	16

Elisabeth Aberer

#	Article	IF	CITATIONS
19	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. Journal of Investigative Dermatology, 2021, 141, 1719-1727.	0.7	14
20	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1705-1712.e4.	3.8	13
21	The influence of religious/spiritual wellâ€being on quality of life in dermatological disease. British Journal of Dermatology, 2016, 174, 1380-1383.	1.5	12
22	Spiritual wellâ€being and coping in scleroderma, lupus erythematosus, and melanoma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 717-728.	0.8	11
23	Co-culture of human fibroblasts and Borrelia burgdorferi enhances collagen and growth factor mRNA. Archives of Dermatological Research, 2018, 310, 117-126.	1.9	10
24	CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study. Archives of Dermatological Research, 2018, 310, 485-493.	1.9	7
25	Anaphylaxis with clonal mast cells in normal looking skin– a new entity?. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 864-872.	5.7	6
26	Spirituality and mood pathology in severe skin conditions: a prospective observational study. Archives of Dermatological Research, 2016, 308, 521-525.	1.9	6
27	Laboratory diagnosis of Lyme neuroborreliosis is influenced by the test used: Comparison of two ELISAs, immunoblot and CXCL13 testing. Journal of the Neurological Sciences, 2014, 347, 96-103.	0.6	5
28	Sclerodermiform porphyria cutanea tarda after torasemide. European Journal of Dermatology, 2015, 25, 484-485.	0.6	5
29	The relationship between existential well-being and mood-related psychiatric burden in Indian young adults with attachment deficits: a cross-cultural validation study. BMC Psychology, 2020, 8, 21.	2.1	5
30	The influence of religious/spiritual exercises on well-being and quality of life in dermatological patients: A quasi-experimental study. Cogent Medicine, 2018, 5, 1499593.	0.7	4
31	Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic Sclerosis. Arthritis Care and Research, 2020, 72, 1041-1048.	3.4	3
32	An Arden-Syntax-based clinical decision support framework for medical guidelinesLyme borreliosis as an example. Studies in Health Technology and Informatics, 2014, 198, 125-32.	0.3	3
33	Medical Photography: Documentation, Art, and the Expression of Human Emotions. Case Reports in Dermatology, 2017, 8, 227-238.	0.8	2
34	Adult morphea en coup de sabre with accompanying regional polymyositis: A separate entity?. Australasian Journal of Dermatology, 2018, 59, e145-e146.	0.7	2
35	Facets of shame are differently expressed in dermatological disease: a prospective observational study. British Journal of Dermatology, 2020, 183, 169-171.	1.5	2
36	Paraneoplastic pemphigus in two pairs of brothers. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e552-e553.	2.4	1

#	Article	IF	CITATIONS
37	Erythema migrans mimicking early morphea. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1325-1327.	0.8	1
38	The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network. Memo - Magazine of European Medical Oncology, 2013, 6, 114-118.	0.5	0
39	AB0169â€Evaluation of frequency and type of physical therapy in more than 3400 patients with systemic sclerosis. , 2017, , .		0
40	AB0181â€Diffusing capacity and clinical characteristics of patients with systemic sclerosis – data from the german network for systemic sclerosis. , 2017, , .		0
41	Heinz Rüegger (2017) Vom Sinn in hohem Alter: Eine theologische und ethische Auseinandersetzung. Zürich: TVZ. ISBN 978-3-290-17871-0; 155 Seiten; Preis 26,90 â,¬ (D); 27,70 â,¬ (A); 29,80 CHF. Spiritual Care, 7, 228-229.	20.18,	0